General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
Renal cell carcinoma (RCC), for adjuvant treatment of adult patients, at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions
Last updated December 15, 2022
Status:
Concluded without agreement
Manufacturer:
Alexion Pharma Canada Corp.
Indication:
Myasthenia Gravis
Last updated December 12, 2022
Status:
Concluded without agreement
Manufacturer:
Alexion Pharma Canada Corp.
Indication:
Neuromyelitis optica spectrum disorder (NMOSD)
Last updated December 12, 2022
Status:
Concluded with an LOI
Manufacturer:
UCB Canada Inc.
Indication:
Psoriasis, moderate to severe plaque
Last updated December 9, 2022
Status:
Concluded with an LOI
Manufacturer:
Pfizer Canada ULC
Indication:
Growth hormone deficiency
Last updated November 28, 2022
Status:
Concluded with an LOI
Manufacturer:
Seagen Canada Inc.
Indication:
Unresectable, locally advanced or metastatic urothelial cancer in adult patients who have previously received a platinum-containing chemotherapy and programmed death receptor-1 or programmed death-ligand 1 inhibitor therapy
Last updated November 28, 2022
Status:
Concluded with an LOI
Manufacturer:
Eli Lilly Canada Inc.
Indication:
Migraine, prevention
Last updated November 22, 2022
Status:
Negotiations were not pursued
Manufacturer:
Biogen Canada Inc.
Indication:
Spinal Muscular Atrophy in adult patients over 18 years of age
Last updated November 14, 2022
Status:
Concluded with an LOI
Manufacturer:
BGP Pharma ULC, d.b.a. Viatris Canada
Indication:
Diabetes Mellitus, Type 1 & 2
Last updated November 14, 2022
Status:
Concluded with an LOI
Manufacturer:
Pendopharm, a division of Pharmascience Inc.
Indication:
Mild to moderate essential hypertension and management of chronic stable angina
Last updated November 14, 2022